Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Amalgamated Bank

Amalgamated Bank reduced its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 10.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,704 shares of the biopharmaceutical company’s stock after selling 4,283 shares during the period. Amalgamated Bank’s holdings in Dynavax Technologies were worth $398,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. AlphaCentric Advisors LLC grew its stake in Dynavax Technologies by 55.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 201,500 shares of the biopharmaceutical company’s stock worth $2,245,000 after buying an additional 71,500 shares during the last quarter. James Investment Research Inc. grew its stake in Dynavax Technologies by 14.1% during the 3rd quarter. James Investment Research Inc. now owns 67,134 shares of the biopharmaceutical company’s stock worth $748,000 after buying an additional 8,304 shares during the last quarter. US Bancorp DE grew its stake in Dynavax Technologies by 291.4% during the 3rd quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 2,034 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Dynavax Technologies by 63.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 25,204 shares of the biopharmaceutical company’s stock worth $281,000 after buying an additional 9,827 shares during the last quarter. Finally, Nisa Investment Advisors LLC grew its stake in Dynavax Technologies by 44.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after buying an additional 1,679 shares during the last quarter. 96.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently commented on DVAX shares. The Goldman Sachs Group lowered their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research note on Thursday, August 8th. HC Wainwright reissued a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.

Dynavax Technologies Trading Down 8.8 %

NASDAQ:DVAX opened at $12.21 on Monday. Dynavax Technologies Co. has a 1 year low of $9.74 and a 1 year high of $15.01. The stock has a market cap of $1.61 billion, a price-to-earnings ratio of 93.93 and a beta of 1.34. The business has a fifty day moving average of $11.39 and a 200-day moving average of $11.31. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.